The Mumbai-based global pharma company, Wockhardt, on Thursday became the first Indian company to get the Drug Controller General of India (DCGI) approval for two of its novel antibiotics, Emrok (injectable) and Emrok O (oral). The new antibiotics will be launched in the next few months in domestic as well as Chinese markets.
The antibiotics are used for acute bacterial skin and skin structure infections, which include diabetic foot infections. The approval is based on a three phase clinical study involving 500 patients in 40 centers across India. While many MNCs have launched their antibiotics in India, there have been no new launches for 15 years in the gram-positive bacterial infections.
In an official press release, Wockhardt Managing Director Murtaza Khorakiwala said, “Wockhardt becomes the first domestic drugmaker to get approval for novel antibiotic drugs discovered, developed and manufactured in India.” He further added that the company saw a huge unmet medical need in this segment.
The company expects to build these antibiotics into a ₹100cr brand over the next two years. After the announcement, Wockhardt’s shares closed at ₹273.85 after a 5.7% high.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.